Overview

Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy

Status:
RECRUITING
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Patients who experienced neutropenia after receiving pegfilgrastim on day 1 of the first round are randomly assigned to either the control or experimental arm. Patients in the control arm continue pegfilgrastim injection on day 1 while patients in the experimental arm will receive pegfilgrastim injection on day 3 to see if changing the pegfilgrastim administration date from day 1 to day 3 starting from the second round of chemotherapy could reduce the incidence of neutropenia
Phase:
PHASE4
Details
Lead Sponsor:
Eunseong Medical Foundation Good GANG-AN HOSPITAL
Collaborator:
Hanmi Pharmaceutical Company Limited
Treatments:
eflapegrastim